| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
|
Hepatology
|
2010
|
3.53
|
|
2
|
Prospective validation of the Barcelona Clinic Liver Cancer staging system.
|
J Hepatol
|
2006
|
3.09
|
|
3
|
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.
|
Gastroenterology
|
2004
|
2.87
|
|
4
|
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
|
Am J Gastroenterol
|
2008
|
2.36
|
|
5
|
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma.
|
Clin Gastroenterol Hepatol
|
2006
|
2.26
|
|
6
|
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.
|
Lancet Oncol
|
2011
|
2.04
|
|
7
|
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.
|
Ann Surg
|
2004
|
1.88
|
|
8
|
Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).
|
Am J Gastroenterol
|
2002
|
1.85
|
|
9
|
Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival.
|
Am J Gastroenterol
|
2004
|
1.83
|
|
10
|
The survival benefit of liver transplantation in hepatocellular carcinoma patients.
|
Dig Liver Dis
|
2010
|
1.53
|
|
11
|
Barrett's epithelium after antireflux surgery.
|
J Gastrointest Surg
|
2005
|
1.52
|
|
12
|
Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA).
|
Ann Surg
|
2012
|
1.50
|
|
13
|
Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers.
|
Hepatology
|
2009
|
1.50
|
|
14
|
Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study.
|
Future Oncol
|
2013
|
1.46
|
|
15
|
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance.
|
Dig Liver Dis
|
2011
|
1.45
|
|
16
|
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience.
|
Gut
|
2010
|
1.29
|
|
17
|
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.
|
J Hepatol
|
2010
|
1.22
|
|
18
|
Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer.
|
Mol Cancer
|
2007
|
1.17
|
|
19
|
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
|
BMC Cancer
|
2008
|
1.16
|
|
20
|
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?
|
Am J Gastroenterol
|
2007
|
1.14
|
|
21
|
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
|
Cancer
|
2014
|
1.13
|
|
22
|
Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma.
|
J Hepatol
|
2005
|
1.13
|
|
23
|
The changing scenario of hepatocellular carcinoma over the last two decades in Italy.
|
J Hepatol
|
2011
|
1.11
|
|
24
|
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma.
|
Am J Gastroenterol
|
2006
|
1.08
|
|
25
|
Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis.
|
Hepatology
|
2013
|
1.08
|
|
26
|
Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma.
|
BMC Cancer
|
2012
|
1.07
|
|
27
|
Adequate interval for hepatocellular carcinoma surveillance.
|
Am J Gastroenterol
|
2013
|
1.05
|
|
28
|
Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment.
|
World J Gastroenterol
|
2011
|
1.03
|
|
29
|
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma.
|
Dig Liver Dis
|
2013
|
1.02
|
|
30
|
Prognosis of untreated hepatocellular carcinoma.
|
Hepatology
|
2014
|
1.01
|
|
31
|
The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
|
Hum Pathol
|
2013
|
1.00
|
|
32
|
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
|
Hepatology
|
2012
|
0.99
|
|
33
|
Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP).
|
Crit Rev Oncol Hematol
|
2006
|
0.96
|
|
34
|
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients.
|
Liver Int
|
2013
|
0.94
|
|
35
|
Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease.
|
Alcohol Alcohol
|
2002
|
0.94
|
|
36
|
Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO).
|
Dig Liver Dis
|
2010
|
0.93
|
|
37
|
Hepatic spleen nodules (HSN).
|
Scand J Gastroenterol
|
2010
|
0.92
|
|
38
|
Re: CDX2 homeotic gene expression in gastric noninvasive neoplasia.
|
Am J Surg Pathol
|
2004
|
0.91
|
|
39
|
Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma.
|
BMC Gastroenterol
|
2012
|
0.91
|
|
40
|
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance.
|
Am J Gastroenterol
|
2007
|
0.90
|
|
41
|
Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma.
|
J Surg Oncol
|
2007
|
0.90
|
|
42
|
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.
|
J Hepatol
|
2012
|
0.88
|
|
43
|
Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.
|
Cancer
|
2010
|
0.88
|
|
44
|
Hepatocellular carcinoma in patients with cryptogenic cirrhosis.
|
Clin Gastroenterol Hepatol
|
2009
|
0.87
|
|
45
|
Gastrointestinal stromal tumors: the histology report.
|
Dig Liver Dis
|
2011
|
0.87
|
|
46
|
Lymphadenectomy in patients with gastric cancer. A critical review.
|
Suppl Tumori
|
2003
|
0.86
|
|
47
|
Advanced precancerous lesions in the liver.
|
Best Pract Res Clin Gastroenterol
|
2013
|
0.86
|
|
48
|
Gastrointestinal stromal tumors: report of an audit and review of the literature.
|
Eur J Cancer Prev
|
2009
|
0.85
|
|
49
|
Chemoprevention of colorectal cancer: feasibility in everyday practice?
|
Eur J Cancer Prev
|
2008
|
0.85
|
|
50
|
Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study.
|
PLoS One
|
2013
|
0.84
|
|
51
|
Hepatocellular carcinoma in patients without cirrhosis in Italy.
|
Dig Liver Dis
|
2012
|
0.83
|
|
52
|
Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention.
|
Eur J Cancer Prev
|
2011
|
0.83
|
|
53
|
Oxidative DNA damage in Barrett mucosa: correlation with telomeric dysfunction and p53 mutation.
|
Ann Surg Oncol
|
2013
|
0.83
|
|
54
|
Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial.
|
Dig Liver Dis
|
2012
|
0.82
|
|
55
|
Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres.
|
Liver Int
|
2013
|
0.82
|
|
56
|
TACE treatment in hepatocellular carcinoma: what should we do now?
|
J Hepatol
|
2012
|
0.82
|
|
57
|
Non-invasive diagnosis of Helicobacter pylori infection: simplified 13C-urea breath test, stool antigen testing, or DNA PCR in human feces in a clinical laboratory setting?
|
Clin Biochem
|
2004
|
0.82
|
|
58
|
Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping.
|
Hum Pathol
|
2011
|
0.82
|
|
59
|
Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype.
|
J Clin Pathol
|
2007
|
0.82
|
|
60
|
Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies.
|
PLoS One
|
2011
|
0.82
|
|
61
|
Bax inhibitor-1 down-regulation in the progression of chronic liver diseases.
|
BMC Gastroenterol
|
2010
|
0.81
|
|
62
|
Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
|
Eur J Cancer Prev
|
2008
|
0.81
|
|
63
|
Sex hormone profile and endometrial cancer risk in primary biliary cirrhosis: a case-control study.
|
Eur J Obstet Gynecol Reprod Biol
|
2002
|
0.81
|
|
64
|
Long-term follow-up of Barrett's epithelium: medical versus antireflux surgical therapy.
|
J Gastrointest Surg
|
2011
|
0.81
|
|
65
|
Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
|
Eur J Gastroenterol Hepatol
|
2006
|
0.80
|
|
66
|
Significance of platelet and AFP levels and liver function parameters for HCC size and survival.
|
Int J Biol Markers
|
2014
|
0.80
|
|
67
|
Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study.
|
HPB (Oxford)
|
2014
|
0.79
|
|
68
|
Immunotherapy for gastric premalignant lesions and cancer.
|
Immunotherapy
|
2012
|
0.79
|
|
69
|
Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC).
|
J Gastroenterol Hepatol
|
2014
|
0.79
|
|
70
|
Non-invasive neoplasia of the stomach.
|
Eur J Gastroenterol Hepatol
|
2005
|
0.79
|
|
71
|
Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges.
|
Dig Dis
|
2012
|
0.79
|
|
72
|
Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.
|
Dig Dis Sci
|
2014
|
0.79
|
|
73
|
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms.
|
Gastroenterology
|
2004
|
0.79
|
|
74
|
Micronuclei and broken eggs in human liver carcinogenesis.
|
Anticancer Res
|
2008
|
0.78
|
|
75
|
Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin's lymphoma.
|
Tumori
|
2008
|
0.78
|
|
76
|
Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy.
|
Am J Clin Pathol
|
2012
|
0.78
|
|
77
|
The war of the worlds: metaplastic versus nonmetaplastic atrophic gastritis.
|
Gastrointest Endosc
|
2011
|
0.77
|
|
78
|
Sorafenib use in the transplant setting.
|
Liver Transpl
|
2014
|
0.77
|
|
79
|
Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead.
|
Hepatology
|
2011
|
0.77
|
|
80
|
Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience.
|
Am J Gastroenterol
|
2012
|
0.76
|
|
81
|
Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era.
|
Hepatol Res
|
2010
|
0.76
|
|
82
|
Gastrin: from pathophysiology to cancer prevention and treatment.
|
Eur J Cancer Prev
|
2014
|
0.76
|
|
83
|
MINT31 methylation in gastric noninvasive neoplasia: potential role in the secondary prevention of gastric cancer.
|
Eur J Cancer Prev
|
2012
|
0.76
|
|
84
|
Apoptosis in alcoholic hepatitis.
|
J Hepatol
|
2002
|
0.76
|
|
85
|
Low alpha-fetoprotein HCC and the role of GGTP.
|
Int J Biol Markers
|
2014
|
0.76
|
|
86
|
Interleukin 1β and tumor necrosis factor-α polymorphisms in autoimmune gastritis.
|
Eur J Gastroenterol Hepatol
|
2011
|
0.76
|
|
87
|
Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea.
|
Liver Int
|
2010
|
0.75
|
|
88
|
The mechanisms underlying hepatitis C virus genotype 3-mediated liver damage.
|
J Hepatol
|
2003
|
0.75
|
|
89
|
Up and down regulation of apoptosis in hepatitis C virus-related liver damage.
|
J Hepatol
|
2004
|
0.75
|
|
90
|
TGF-beta and hepatocellular carcinoma.
|
Hepatology
|
2008
|
0.75
|
|
91
|
Digestive oncology: It's now or never.
|
Dig Liver Dis
|
2011
|
0.75
|
|
92
|
Changes in microRNA expression during disease progression in patients with chronic viral hepatitis.
|
Liver Int
|
2015
|
0.75
|
|
93
|
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
|
Cancer Chemother Pharmacol
|
2011
|
0.75
|
|
94
|
Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study.
|
J Clin Gastroenterol
|
2017
|
0.75
|
|
95
|
Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination.
|
Cancer Immunol Immunother
|
2011
|
0.75
|
|
96
|
Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study.
|
Liver Int
|
2010
|
0.75
|
|
97
|
Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori: scratch and win.
|
Scand J Gastroenterol
|
2005
|
0.75
|